ARS Pharmaceuticals, Inc. SPRY

Set alert

Price alert · SPRY

All alert types
3.02 USD -0.03 -1.15%

As of Nov 3, 10:13 AM ET

Bid
3.01 × 2
Ask
3.02 × 2
2.98 Day range 3.11
2.91 52-week range 13.15
YTD
-74.12%
1 year
-65.02%
Open
3.05
Prev close
3.05
Mkt cap
299.83M
Vol
283.04K
Avg vol
1.65M
EPS
-1.96
P/E
0.00
Div yield
0.00%
More statistics
Low
2.98
High
3.11
Forward P/E
-11.01
Beta
0.83
Short ratio
13.70
Inst. own
95.47%
Dividend
0.00
Ex-div date
Earnings
Aug 13, 2026
50-d avg
8.64
200-d avg
9.38
1y target
28.80

6M chart

Chart tools
Interval

Events in this range
  • May 15, 2026Earnings: -0.61; estimate -0.53; surprise -15.09%
  • May 28, 2026Rating: Cantor Fitzgerald · Overweight → Overweight
  • Aug 13, 2026Earnings: —; estimate -0.47655; surprise —%
Signals (22)
NameDateAgo
RSI: OversoldOct 30, 20264 days ago
MACD: Sell SignalOct 28, 20266 days ago
MACD: Buy SignalSep 29, 20261 month ago
RSI: OversoldSep 25, 20261 month ago
RSI: OversoldSep 14, 20261 month ago
MACD: Sell SignalSep 9, 20261 month ago
MACD: Buy SignalAug 7, 20262 months ago
RSI: OversoldJul 20, 20263 months ago
SMA: BearishJun 25, 20264 months ago
SMA: BearishJun 25, 20264 months ago
MACD: Sell SignalJun 25, 20264 months ago
SMA: BullishJun 8, 20264 months ago
SMA: BearishJun 5, 20265 months ago
SMA: BullishJun 4, 20265 months ago
SMA: BearishJun 2, 20265 months ago
SMA: BullishMay 28, 20265 months ago
SMA: BullishMay 27, 20265 months ago
MACD: Buy SignalMay 27, 20265 months ago
SMA: BearishMay 22, 20265 months ago
SMA: BullishMay 21, 20265 months ago

Newest 20 of 22.

Analyst view

Consensus: none

Price target (mean) 28.80 +855.2% upside
Target (low)
25.00
Target (mean)
28.80
Target (high)
32.00
Ratings (0m) 5 5 buy · 0 hold · 0 sell
  • Strong buy0
  • Buy5
  • Hold0
  • Sell0
  • Strong sell0

Recommendation trend

  • This month 5
  • 1 month ago 5
  • 2 months ago 7
  • 3 months ago 6

Earnings and revenue estimates

Consensus for the coming quarters and fiscal years

SPRY analyst estimates
PeriodEPS estimateLow – highYear agoEPS growthRevenue estimateRevenue growthAnalysts
Current quarter-0.53-0.61 – -0.47-0.46-15.2%31.53M+100.6%3
Next quarter-0.33-0.40 – -0.20-0.52+36.5%51.31M+57.9%3
Current year-1.76-2.05 – -1.45-1.74-1.1%149.35M+77.2%4
Next year-0.9575-1.41 – -0.44-1.76+45.6%273.65M+83.2%4

Upgrades and downgrades

The latest rating changes

SPRY analyst upgrades and downgrades
DateFirmActionFromTo
May 28, 2026Cantor FitzgeraldMaintainedOverweightOverweight
Sep 4, 2025Roth CapitalInitiated—Buy
Mar 7, 2025ScotiabankInitiated—Sector Outperform
Jan 14, 2025Raymond JamesMaintainedStrong BuyStrong Buy
Jan 13, 2025Leerink PartnersMaintainedOutperformOutperform
Oct 8, 2024Cantor FitzgeraldReiteratedOverweightOverweight
Sep 20, 2024Leerink PartnersMaintainedOutperformOutperform
Sep 16, 2024Cantor FitzgeraldReiteratedOverweightOverweight
Sep 9, 2024Cantor FitzgeraldReiteratedOverweightOverweight
Aug 20, 2024Cantor FitzgeraldInitiated—Overweight
Aug 13, 2024Raymond JamesUpgradeOutperformStrong Buy
Jul 25, 2024Raymond JamesInitiated—Outperform
Mar 11, 2024WedbushReiteratedOutperformOutperform
Mar 5, 2024Leerink PartnersUpgradeMarket PerformOutperform
Nov 13, 2023WedbushMaintainedOutperformOutperform
Sep 21, 2023WedbushMaintainedOutperformOutperform
Sep 20, 2023William BlairDowngradeOutperformMarket Perform
Aug 14, 2023WedbushReiteratedOutperformOutperform
Jun 21, 2023WedbushMaintainedOutperformOutperform
May 18, 2023WedbushReiteratedOutperformOutperform
May 12, 2023WedbushReiteratedOutperformOutperform
May 10, 2023WedbushReiterated—Outperform
Jan 31, 2023WedbushInitiated—Outperform
Jan 4, 2023William BlairInitiated—Outperform
Dec 13, 2022SVB LeerinkInitiated—Outperform